


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 9, 2006 (use as many sheets as necessary)				Complete if Known Application Number 10/527,666 Filing Date 9/15/2003 First Named Inventor Christophe de ROMEUF Group Art Unit 1644 Examiner Name Crowder, Chun Attorney Docket Number 065691-0387	
Sheet	1	of	1		



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
C.C.	A1	6,180,377	B1	MORGAN et al.	01/30/2001	
C.C.	A2	2003-175969	A1	BELIARD et al.	09/18/2003	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
C.C.	A3	WO	01/77181	A2	Laboratoire Francais du Francionnement et des Biotechnologies	10/18/2001	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
C.C.	A4	CARTRON et al., "Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene," Blood, February 1, 2002, vol. 99, no. 3, pp. 754-758.		
	A5	SHIELDS et al., "Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human FcγRIIIa and Antibody-dependent Cellular Toxicity," J. Biol. Chem., July 26, 2002, vol. 277, no. 30, pp. 26733-26740.		
	A6	SHINKAWA et al., "The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity," J. Biol. Chem., January 31, 2003, vol. 278, no. 5, pp. 3466-3473.		
	A7	VIDOVIC et al., "Selective Apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody," Cancer letters, 1998, vol. 128, pp. 127-135.		
C.C.	A8	WRIGHT et al., "Effect of glycosylation on antibody function: implications for genetic engineering," Trends in Biology, 1997, vol. 15, no. 1, pp. 26-32.		

Examiner Signature		Date Considered	12/14/06
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.